EU Clinical Trial 2018-004445-17

A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study of AP30663 Given Intravenously for Cardioversion in Patients with Atrial Fibrillation  May 30, 2019

Main objective of the trial: The primary objective of the study is to demonstrate efficacy of AP30663 on the basis of the ability to convert AF following intravenous administration.


AP30663 Atrial fibrillation

JSON preview

Similar records


Source:  EMA Last updated:  Jun 5, 2019

From, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.